Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
   PubMed Web of Science ®Google Scholar
• Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 2012; 48:187 - 95; http://dx.doi.org/10.1016/j.ejca.2011.10.021; PMID: 22100904
   PubMed Web of Science ®Google Scholar
• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27:165 - 76; http://dx.doi.org/10.1053/ctrv.2000.0210; PMID: 11417967
   PubMed Web of Science ®Google Scholar
• Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 1994; 32:73 - 84; http://dx.doi.org/10.1007/BF00666208; PMID: 7819589
   PubMed Web of Science ®Google Scholar
• Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011; 48:6 - 15; http://dx.doi.org/10.1016/j.bone.2010.07.015; PMID: 20643235
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells. Adv Exp Med Biol 2007; 601:213 - 23; http://dx.doi.org/10.1007/978-0-387-72005-0_22; PMID: 17713008
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16:348 - 53; http://dx.doi.org/10.1097/PPO.0b013e3181eb3358; PMID: 20693846
   PubMed Web of Science ®Google Scholar
• Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40:2969 - 75; http://dx.doi.org/10.1002/eji.201040895; PMID: 21061430
   PubMed Web of Science ®Google Scholar
• Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22:238 - 44; http://dx.doi.org/10.1016/j.coi.2010.01.021; PMID: 20171075
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162 - 74; http://dx.doi.org/10.1038/nri2506; PMID: 19197294
   PubMed Web of Science ®Google Scholar
• Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000; 96:3838 - 46; PMID: 11090068
   PubMed Web of Science ®Google Scholar
• Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003; 102:2138 - 45; http://dx.doi.org/10.1182/blood-2003-01-0190; PMID: 12750171
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67:4507 - 13; http://dx.doi.org/10.1158/0008-5472.CAN-06-4174; PMID: 17483367
   PubMed Web of Science ®Google Scholar
• Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16:53 - 65; http://dx.doi.org/10.1016/j.semcancer.2005.07.005; PMID: 16168663
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64:5839 - 49; http://dx.doi.org/10.1158/0008-5472.CAN-04-0465; PMID: 15313928
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172:989 - 99; PMID: 14707072
   PubMed Web of Science ®Google Scholar
• Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222:162 - 79; http://dx.doi.org/10.1111/j.1600-065X.2008.00602.x; PMID: 18364001
   PubMed Web of Science ®Google Scholar
• Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13:23 - 35; http://dx.doi.org/10.1016/j.ccr.2007.12.004; PMID: 18167337
   PubMed Web of Science ®Google Scholar
• Yang L, Edwards CM, Mundy GR. Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. J Bone Miner Res 2010; 25:1701 - 6; http://dx.doi.org/10.1002/jbmr.154; PMID: 20572008
   PubMed Web of Science ®Google Scholar
• Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6:409 - 21; http://dx.doi.org/10.1016/j.ccr.2004.08.031; PMID: 15488763
   PubMed Web of Science ®Google Scholar
• Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, et al. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res 2011; 71:822 - 31; http://dx.doi.org/10.1158/0008-5472.CAN-10-2993; PMID: 21189326
   PubMed Web of Science ®Google Scholar
• Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007; 67:11438 - 46; http://dx.doi.org/10.1158/0008-5472.CAN-07-1882; PMID: 18056472
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Hood KC, Zobel LC, Shafer LR, Coles M, Toth B. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int Immunopharmacol 2007; 7:140 - 51; http://dx.doi.org/10.1016/j.intimp.2006.09.021; PMID: 17178380
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Gabrilovich DI. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 2006; 25:323 - 31; http://dx.doi.org/10.1007/s10555-006-9002-6; PMID: 16983515
   PubMed Web of Science ®Google Scholar
• Sterling JA, Oyajobi BO, Grubbs B, Padalecki SS, Munoz SA, Gupta A, et al. The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 2006; 66:7548 - 53; http://dx.doi.org/10.1158/0008-5472.CAN-06-0452; PMID: 16885353
   PubMed Web of Science ®Google Scholar
• Burger EH, Van der Meer JW, van de Gevel JS, Gribnau JC, Thesingh GW, van Furth R. In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes. J Exp Med 1982; 156:1604 - 14; http://dx.doi.org/10.1084/jem.156.6.1604; PMID: 7175438
   PubMed Web of Science ®Google Scholar
• Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207:2439 - 53; http://dx.doi.org/10.1084/jem.20100587; PMID: 20876310
   PubMed Web of Science ®Google Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584 - 93; http://dx.doi.org/10.1038/nrc867; PMID: 12154351
   PubMed Web of Science ®Google Scholar
• Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL, Beneton M, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987; 13:41 - 9; PMID: 3102281
   PubMed Web of Science ®Google Scholar
• Suva LJ, Griffin RJ, Makhoul I. Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer 2009; 16:703 - 13; http://dx.doi.org/10.1677/ERC-09-0012; PMID: 19443538
   PubMed Web of Science ®Google Scholar
• Lathers DM, Clark JI, Achille NJ, Young MR. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother 2004; 53:422 - 30; http://dx.doi.org/10.1007/s00262-003-0459-7; PMID: 14648070
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003; 63:4441 - 9; PMID: 12907617
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006; 55:237 - 45; http://dx.doi.org/10.1007/s00262-005-0048-z; PMID: 16047143
   PubMed Web of Science ®Google Scholar
• Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98:1544 - 9; http://dx.doi.org/10.1172/JCI118947; PMID: 8833902
   PubMed Web of Science ®Google Scholar
• Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55:3551 - 7; PMID: 7627963
   PubMed Web of Science ®Google Scholar